diabetes cure final mona samahy
TRANSCRIPT
-
8/14/2019 Diabetes Cure Final Mona Samahy
1/70
-
8/14/2019 Diabetes Cure Final Mona Samahy
2/70
-
8/14/2019 Diabetes Cure Final Mona Samahy
3/70
Diabetes Mellitus (DM)
A group of metabolic diseases characterized byhyperglycemia, resulting from defects in insulinsecretion, action or both.
The chronic hyperglycemia of diabetes is associated withlong-term damage, dysfunction and failure of variousorgans, especially the eyes, kidneys, nerves, heart andblood vessels.
It is the most common endocrine metabolic disorder of childhood and adolescence.
-
8/14/2019 Diabetes Cure Final Mona Samahy
4/70
Etio lo gy and Patho genes is
-
8/14/2019 Diabetes Cure Final Mona Samahy
5/70
Pathogenesis of type 1 diabetes
-
8/14/2019 Diabetes Cure Final Mona Samahy
6/70
The clinical and biological characteristics of different subtypes of type 1 diabetes
Type 1a Type 1b Type 1c
Signs of anti-isletautoimmunity
+ - -
Duration of symptomsBefore diagnosis
8 months 7 months < 1 week
Ketosis, ketoacidosisat diagnosis
frequent frequent constant
Blood glucose levels
at diagnosis
HbAlc at diagnosis Normal orslightly elevated
-
8/14/2019 Diabetes Cure Final Mona Samahy
7/70
The war on Diabetes Mellitus
-
8/14/2019 Diabetes Cure Final Mona Samahy
8/70
The war on DM
Starts by attempts to identify environmentaldeterminants of DM in the young whichfocus to identify dietary , infectious , and
other environmental tr iggers of type 1a DMin genetically at risk chi ldren .
Identification of such triggers could lead to thestudy and implementation of primary prevention.
-
8/14/2019 Diabetes Cure Final Mona Samahy
9/70
Through
1- Pr imary Prevention
Avoidance of dietary
offender
Immunization against an
infectious trigger
-
8/14/2019 Diabetes Cure Final Mona Samahy
10/70
TRIGR STUDY
The trial to reduce IDDM in thegenetically at risk is ongoing.
Its focus is to determine whether delayedexposure to or avoidance of certainfood proteins will reduce the risk of
developing type 1 DM in infants atGenetic Risk.
-
8/14/2019 Diabetes Cure Final Mona Samahy
11/70
Type 1a DM is the autoimmune form whose major geneticrisk traits are defined on certain HLA DR/DQ alleles.
The genes mutation will not be correctable by avoidance of dietary or infectious agents.
However, insights gained from these mutations may
facilitate ultimate prevention strategies such asimmunization with specific segments or epitopes of theinsulin molecule to limit autoimmune self aggression.
The results of primary prevention trials are still unknown(June, 2008)
-
8/14/2019 Diabetes Cure Final Mona Samahy
12/70
-
8/14/2019 Diabetes Cure Final Mona Samahy
13/70
Even if these studies identify one or severalmagic bullets for arresting or preventing theprogression of DM, we would still be
confronted with the problem of cu r ing or revers ing established disease.
2- Secondary Prevention
-
8/14/2019 Diabetes Cure Final Mona Samahy
14/70
Insulin has been the gold standardtherapy for DM since its discovery.
It remains the only pharmacologictherapy for type 1DM
-
8/14/2019 Diabetes Cure Final Mona Samahy
15/70
Before insulin wasdiscovered in 1921,everyone with type
1 diabetes diedwithin weeks to years of its onset
Before Insulin.Whats After?
JL on 12/15/22 and 2 mos later
-
8/14/2019 Diabetes Cure Final Mona Samahy
16/70
Insulin Therapy in Type 1 Diabetesis a must
-
8/14/2019 Diabetes Cure Final Mona Samahy
17/70
Ideal Insulin Regimens Type 1 DM
Minimizes nocturnal
hypos OptimizeFBS
Minimizes late morning andafternoon hypos
Basal -Bo lus Regim en
The challenge is to
Com e as c lose as pos s ib le to norm oglyc emia and reduce hyp oglyc emia .
-
8/14/2019 Diabetes Cure Final Mona Samahy
18/70
-
8/14/2019 Diabetes Cure Final Mona Samahy
19/70
Although molecularly producedinsulin administered 4 or 5 times perday can provide a physiologic
regulation, yet it is not able to preventdiabetic complications that account forthe morbidity and mortality of diabetic
patients.
-
8/14/2019 Diabetes Cure Final Mona Samahy
20/70
Also insulin does not eliminate thetype1 DM hallmark : BETA- CELLSPECIFIC AUTOIMMUNITY.
In other words
Insulin is not a cure
-
8/14/2019 Diabetes Cure Final Mona Samahy
21/70
1. Either replace or maintain the functionalintegrity of the natural insulin-producing tissue.
2. Must at least control the autoimmunityor eliminate it altogether.
3. Easy to apply to a large number of patients
A successful cure must meet
the following criteria:
-
8/14/2019 Diabetes Cure Final Mona Samahy
22/70
Criter ion 1
Has been partially realized by allogenic islettransplantation.
-
8/14/2019 Diabetes Cure Final Mona Samahy
23/70
Development of Insulin-Secreting Pancreatic-Like Cells FromMouse Embryonic Stem Cells.
-
8/14/2019 Diabetes Cure Final Mona Samahy
24/70
Criter ion 2
Has been partially realized usingmonoclonal antibodies specific for T-cell
surface proteins.
Criter ion 3
Has yet to be realized
-
8/14/2019 Diabetes Cure Final Mona Samahy
25/70
New Approach to (fulfill the 3 criteria)
-
8/14/2019 Diabetes Cure Final Mona Samahy
26/70
A non-insulin based therapy,
With a focus on
Cell-Based Immunomodulation
Hoping for cure
-
8/14/2019 Diabetes Cure Final Mona Samahy
27/70
All proposals of treatment in thepast and recently are depending on
discoveries in understanding theimmune pathophysiology of
destruction of pancreatic cells that
results in DM.
-
8/14/2019 Diabetes Cure Final Mona Samahy
28/70
Nature of autoimmunity in type 1a DM
The major affectors of -cell destructionare T cells reactive to -cell-specificantigens.
A strong genetic predisposition is the keyfor genetic susceptibility loci thataffect genesis, function and survival of
immune cell subsets including T cells anddendritic cells.
Type 1 Diabetes as immune destruction of beta
-
8/14/2019 Diabetes Cure Final Mona Samahy
29/70
APC
T-cellT-cell
B-cell
Inflammatorycell
Cytokines
Beta celldeath
Type 1diabetes
Antibodies
CytotoxicT-cell Beta cell
Beta cellantigens Fas
(IL1, TNF , NO)
Th1 (IL2, IFN )
(ICA, IAA, IA2, GAD65)
Type 1 Diabetes as immune destruction of betacells
-
8/14/2019 Diabetes Cure Final Mona Samahy
30/70
-
8/14/2019 Diabetes Cure Final Mona Samahy
31/70
The epitope spreading phenomenon i.e.expansion of newly recognized antigens
observed in the islet inflammation is due to:
Islet-reactive T cellsthat were generatedin the thymus early
in ontogeny
Generation and survivalof T cells activated inthe periphery by these
new antigens
-
8/14/2019 Diabetes Cure Final Mona Samahy
32/70
There is a pathologic vicious circle of continuouspresentation of old and new antigens, collected by the
dendritic cells (DC) from the newly destroyed -cells tonaive T cells in the pancreatic lymph nodes eventually
go back to the pancreas to kill other -cells.
This vicious circle does not allow the recovery of theinsulin secreting cells, even when the physiologic
homeostasis process tries to substitute the lost cellswith new cells.
-
8/14/2019 Diabetes Cure Final Mona Samahy
33/70
Therefore, an approach developed to stop
autoimmunity in already diabetic patients,could possibly facilitate the recovery of
autologous insulin production.
So , safe induction of an autoimmunity freestatus might became a new promising
therapy for type 1a DM.
-
8/14/2019 Diabetes Cure Final Mona Samahy
34/70
In the past 20 years, researches have mademany promises to cure type 1 DM. Only
recently it has been possible to clinicallyimplement a limited number of successes.
-
8/14/2019 Diabetes Cure Final Mona Samahy
35/70
Autologous transplantation of hematopoietic stem cellenriched BM was used to treat type 1 DM.
The effects were limited to simple postponement of DM recurrence, i.e.: just delayed by the timenecessary for the transplanted BM to reorganize
itself and to reestablish all of its immunocompetentcell subpopulations.
Autologous Bone Marrow Transplantation.
-
8/14/2019 Diabetes Cure Final Mona Samahy
36/70
The autologous BM did not change the patient'sgenetic characteristics under which tolerance forthe insulin producing beta cells was not achievedin the first place.
So , Autoimmunity easily recurred.
Autologous Bone Marrow Transplantation.
BMT can encourage
-
8/14/2019 Diabetes Cure Final Mona Samahy
37/70
gbeta cell regeneration
Regeneration of beta cellsin diabetic NOD mice
A) Infiltration of T cells destroys beta cells
B) After BMT infusion, signs of autoimmune destructiondiminish
C) Insulin-producing cells start toappear (red)
D) 4 mo after BMT infusion, seeproliferation of insulin-producingcells (red)
-
8/14/2019 Diabetes Cure Final Mona Samahy
38/70
Another approach was developed to modify the genetic characteristics of apatient BM-derived stem cells in vitrowhich will result in T-cells or (APC) thatcannot initiate an autoimmune response.(maybe transferable to clinical trials in the nearfuture)
-
8/14/2019 Diabetes Cure Final Mona Samahy
39/70
This was achieved by:
Transduction of BM-derived stem cells withprotective (non diabetogenic) HLA transgenes.
Infusion of the engineered cells will culminate inrepopulation of the thymus with protectiveHLA-expressing APCs.
This in turn will decrease the probability that T cells with diabetogenic T cell receptors matureand exit into the periphery.
-
8/14/2019 Diabetes Cure Final Mona Samahy
40/70
It is postulated that the Rest per iod from the
autoimmune destructive process permitsregeneration of endogenous cells frompancreatic stem cells within the pancreaticducts or islets.
The suppression of the immune environmentby several means was conclusively shown
to be the mechanism that resulted inrecovery from type 1a DM in NOD mouse.
-
8/14/2019 Diabetes Cure Final Mona Samahy
41/70
Two novel recent mechanisms involvingcell based immunomodulation aimed at
producing a cure for type 1a DM :
1. Diabetes-suppressive autologous DC.
2. Diabetes-suppressive microsphere vaccine
-
8/14/2019 Diabetes Cure Final Mona Samahy
42/70
1. Diabetes-suppressive autologous DC.
The first clinically adapted immunoregulatorycell therapeutic
-
8/14/2019 Diabetes Cure Final Mona Samahy
43/70
Why dendr i tic cel ls?
DC are the body's sentinels largelyresponsible for host surveillance againstmicro-environmental anomaliesincluding pathogen invasion, infection,and damaged tissue architecture, while
coordinating the mechanisms of self
tolerance.
-
8/14/2019 Diabetes Cure Final Mona Samahy
44/70
DC continously traffic throughout all bodytissues sampling molecules from their
surroundings, where it is believed theymaintain potentially autoreactiveimmune cells in quiescence eitherdirectly or via indirect regulatory
immune cell networks.
Why dendr i tic cel ls?
When DC encounter local disruption of tissue
-
8/14/2019 Diabetes Cure Final Mona Samahy
45/70
archi tectur e & elevated proinf lammatory signal f rom infected cel ls:
Undergo maturationthrough a series of internal changes.
Migrate away from thesite of danger and into
the closest LNs.
Within the LNs, the DC, as a powerful APC,initially interacts using its class I or class IIMHC / peptide complex with the TCR present on a nave T cell. This will constitutethe so-called f irst signal for T-cell activation.
-
8/14/2019 Diabetes Cure Final Mona Samahy
46/70
To bring a T cell to full activation, asubsequent contact between receptors on bothAPC & T cell (Co receptors) is necessary.
Co-stimulatory molecules present on the APCwith their counterparts on the T cell interactto further stabilize the signal of activationbetween the two cells, thus providing
the second signal.
-
8/14/2019 Diabetes Cure Final Mona Samahy
47/70
Absence of this co-stimulatory molecule binding
and consequently lack of secondary signalgeneration has been shown to lead toimpaired activation of the responding T cell,eventually bring it to functional anergy or apoptosis .
This is indeed the outcome of many
immunosuppressive strategies aimed at co-stimulation blockade.
-
8/14/2019 Diabetes Cure Final Mona Samahy
48/70
Many investigations support the concept that
functionally immature DC (characterized bylow to absent co-stimulation) lead to Immune hyporesponsiveness .
Exogenous administration of functionallyimmature DC achieves long term and stable allograft survival in a variety of mouse andrat models and prevents a number of autoimmune diseases.
-
8/14/2019 Diabetes Cure Final Mona Samahy
49/70
Recently
I n vitro administration of nuclear factor-kappa (NFB) decays to DC as well as directtargeting of CD40, CD80 and CD86 withantisense oligodeoxyribonucleotides (AS-ODN) reduces co-stimulatory molecule levelsproducing functionally immature DC capable
of preventing or reversing new-onset DM in theNOD mouse.
-
8/14/2019 Diabetes Cure Final Mona Samahy
50/70
Numerous clinical trials have safelyused DC-based treatments forcancer therapy providing the basisfor clinical adaptation of DCadministration for Type 1aDM ttt.
-
8/14/2019 Diabetes Cure Final Mona Samahy
51/70
-
8/14/2019 Diabetes Cure Final Mona Samahy
52/70
These DC which express low levels of CD40, CD80 andCD86 are injected into the patient by ID route at ananatomical site proximal to the pancreas.
DC will migrate to the nearest LNs where they will startto interrupt the vicious circle that maintains islet-specific inflammation i.e., insulitis.
This therapeutic approach should be more successful
when DC injections start close to the clinical onset of DM.
-
8/14/2019 Diabetes Cure Final Mona Samahy
53/70
I N TH E PANCREAS
DC acquire -cell specific antigens fromapoptotic cells, leading to the eventual displayof these antigens to T cells in the pancreas-
draining LNs. The lack of co-stimulatory molecules will result in
anergizing signal to the T cells, and interruptthe T cell mediated anti-beta-cell epitopespreading phenomenon.
-
8/14/2019 Diabetes Cure Final Mona Samahy
54/70
The cessation of the autoimmune diabetogenic insultshould be sufficient to:
Promote rescue of still present insulin producing cells and/or
Promote neogenesis of other insulin producingcells in the pancreas, even after the disease onset.
This tri al is underway at (6/2008) & once safety hasbeen demonstrated, a phase I I efficacy trialwill start, involving new onset diabetic patients.
-
8/14/2019 Diabetes Cure Final Mona Samahy
55/70
-
8/14/2019 Diabetes Cure Final Mona Samahy
56/70
2. Diabetes Suppressive microspherevaccine
Diabetes Suppressive microsphere vaccine
-
8/14/2019 Diabetes Cure Final Mona Samahy
57/70
Diabetes Suppressive microsphere vaccine
In spite of the promise of the previous study,many cumbersome logistical requirements togenerate these diabetes-suppressive DC have
been encountered.
This may limit the future enrollment of new onsetdiabetic children in the efficacy phase of thetrial.
-
8/14/2019 Diabetes Cure Final Mona Samahy
58/70
Difficulties:
Leukopheresis takes 2 or 3 hours to provide sufficientprecursors cells to generate the number of DCnecessary for six to eight injections.
The obtained DC should be exposed to AS-ODN in GMPfacilities in which the laboratory practices arefrequently difficult to reproduce. GMP facilities arefrequently located far away from the clinic where thepatients are treated.
Many DC are lost during the freezing/thawing procedures.
-
8/14/2019 Diabetes Cure Final Mona Samahy
59/70
In an effort to avoid these steps, an alternativemethod to stabilize DC immaturity directlyin vivo using microparticle carriers of
immunomodulating agents like AS-ODN(microsphere delivery system) have beendone.
-
8/14/2019 Diabetes Cure Final Mona Samahy
60/70
This microparticle carriers (microspheredelivery system) is directed against 3 keycostimulatory molecules:
CD40CD80
CD86
Essential for normal immune response
-
8/14/2019 Diabetes Cure Final Mona Samahy
61/70
-
8/14/2019 Diabetes Cure Final Mona Samahy
62/70
This microsphere delivery system in
which AS-ODN have beenincorporated, is named Baxter H ealthcare' s PROM AXX .
The inert PROMAXX microspheretechnology has been shown to besafe and effective in human trials.
-
8/14/2019 Diabetes Cure Final Mona Samahy
63/70
More importantly, when administeredin vivo, this technology is neutralwith respect to DC maturation
state compared with the knownimmunostimulatory properties of other microsphere formulations.
-
8/14/2019 Diabetes Cure Final Mona Samahy
64/70
Other polyplex formulations have an inherent
capacity to induce the upregulation of co-stimulatory proteins at the DC surface,whereas the PROMAXX technology doesnot.
This neutrality on DC maturation is a criticalcriterion in adopting microsphere chemistryfor immunosuppressive objectives where DCare involved as mediators.
-
8/14/2019 Diabetes Cure Final Mona Samahy
65/70
They predict that once all preclinical studiesare completed, a phase I/II trial can beinitiated.
The microspheres are simple to manufactureto clinical grade on a large scale and donot involve the cumbersome logistics for
DC based therapy.
-
8/14/2019 Diabetes Cure Final Mona Samahy
66/70
-
8/14/2019 Diabetes Cure Final Mona Samahy
67/70
This novel microsphereformulation represents the f ir st
diabetes suppressive and reversing nucleic acid vaccine that confers an
immunoregulatory phenotype toendogenous DC.
H l i i l
-
8/14/2019 Diabetes Cure Final Mona Samahy
68/70
How long is a single courseof microsphere particleseffective?
Does response wane withrepeated injection?
These questions remain to be answered.
But, if it's effective NEW ERA intreating type 1 DM will appear.
The light at the end
-
8/14/2019 Diabetes Cure Final Mona Samahy
69/70
The light at the end
of the tunnel for
Diabetes Cure
-
8/14/2019 Diabetes Cure Final Mona Samahy
70/70